ClinicalTrials.gg

Program

AHB-171

A development code. Also written as “AHB-171 Injection”.

Its studies are mostly in Hepatitis B, Chronic · Hepatitis B, led by 2 companies.

Furthest: phase 2, since Jun 2, 20263 company-led studies, 3 open or runningNext primary completion: Oct 8, 2027 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Ausper Biopharma22 open or runningphase 2since Jun 2, 2026Mar 30, 2026Dec 30, 2027phase 1 · NCT07511218
AusperBio Therapeutics11 open or runningphase 1since May 7, 2026May 7, 2026Oct 8, 2027phase 1 · NCT07617194

How these companies relate is not in the registry. A license or acquisition is shown only with a dated source, such as a company release or filing.

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Mar 30, 2026First study: phase 1 study in Hepatitis B, ChronicNew to Ausper BiopharmaAusper Biopharma · NCT07511218 · 110 planned · China
  2. May 7, 2026AusperBio Therapeutics's first study: phase 1 study in Hepatitis B, ChronicNew to AusperBio TherapeuticsAusperBio Therapeutics · NCT07617194 · 144 planned · Hong Kong, New Zealand
  3. Jun 2, 2026Phase 2 study in Hepatitis BPhase 2 reachedAusper Biopharma · NCT07630727 · 138 planned · China

Ahead

  1. Oct 8, 2027Primary completion: phase 1 study in Hepatitis B, ChronicAusperBio Therapeutics · NCT07617194
  2. Dec 30, 2027Primary completion: phase 1 study in Hepatitis B, ChronicAusper Biopharma · NCT07511218
  3. Mar 31, 2029Primary completion: phase 2 study in Hepatitis BAusper Biopharma · NCT07630727

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusLed byPrimary completionSize
NCT07630727Hepatitis B · China2RecruitingAusper BiopharmaMar 31, 2029138
NCT07617194Hepatitis B, Chronic · Hong Kong, New Zealand1Not yet recruitingAusperBio TherapeuticsOct 8, 2027144
NCT07511218Hepatitis B, Chronic · China1RecruitingAusper BiopharmaDec 30, 2027110

How it is read

Names in the registry

  • “AHB-171 Injection”, 2 entries
  • “AHB-171”, 1 entry

Codes read as this program: AHB171.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.